Scientific deep-dive
Does Semaglutide Slow Aging? What the Longevity Evidence Shows
No trial has tested whether semaglutide slows aging. SELECT and FLOW found fewer deaths from any cause in people with heart or kidney disease, and the only aging-clock result is a post hoc 32-week analysis in 84 people with HIV.
No trial has tested whether semaglutide slows aging or lengthens life. Two large outcome trials did count deaths. SELECT enrolled 17,604 people who had heart disease plus overweight or obesity. They had a lower rate of death from any cause on semaglutide (hazard ratio 0.81), but death was not the trial’s primary endpoint.[3] In FLOW, people with type 2 diabetes and kidney disease had a 20% lower risk of death from any cause.[4] Those are fewer deaths in sick people. The only “slower aging” finding is a post hoc analysis of epigenetic clocks in 84 people with HIV over 32 weeks.[1] Their samples came from a semaglutide trial designed to measure abdominal fat.
The longevity evidence, sorted by what it measured
| Study | Who and how long | Endpoint | Result | Hard outcome? |
|---|---|---|---|---|
| SELECT mortality analysis[3] | 17,604 adults with heart disease and BMI ≥27, no diabetes; about 3.3 years | Death from any cause | HR 0.81 (95% CI 0.71–0.93) | Yes, but not the primary endpoint |
| FLOW[4] | 3,533 adults with diabetic kidney disease; median 3.4 years | Death from any cause (confirmatory secondary) | HR 0.80 (0.67–0.95) | Yes |
| ESSENCE[5] | 800 of 1,197 adults with MASH and fibrosis; 72-week interim | Liver biopsy | Steatohepatitis resolved in 62.9% vs 34.3% | No, histology |
| HIV lipohypertrophy trial[1] | 84 adults with HIV; 32 weeks | Epigenetic clocks (post hoc) | Several clocks slowed | No, surrogate |
| SLIM LIVER[6] | 41 adults with HIV and fatty liver; 24 weeks, no placebo | Epigenetic clocks (post hoc) | No clear group-wide shift | No, surrogate |
| Mendelian randomization[7] | Genetic data, no drug given | Frailty, PhenoAge, telomeres, longevity | Mixed; weight-lowering via GLP-1 receptor linked to none | No, genetic proxy |
SELECT: fewer deaths from any cause, as a secondary finding
SELECT enrolled adults aged 45 and over with established cardiovascular disease, a BMI of at least 27 and no diabetes, and gave them semaglutide 2.4 mg weekly or placebo. Its primary endpoint bundled three events: a nonfatal stroke, a nonfatal heart attack, or death from a cardiovascular cause. One of them struck 6.5% of the semaglutide group and 8.0% of the placebo group. The ratio of hazards was 0.80, with a 95% interval from 0.72 to 0.90.[2] Subgroups of the trial are less certain. In participants whose blood tests suggested liver fibrosis, the largest of three reported reductions was the only one that missed statistical significance.
Deaths were counted and adjudicated throughout. A separate analysis of the 833 deaths in the trial put the hazard ratio for death from any cause at 0.81, with a 95% interval running from 0.71 to 0.93. Cardiovascular death alone came in at 0.85, with an interval (0.71 to 1.01) that crossed no effect. Non-cardiovascular death was 0.77 (0.62 to 0.95), and the largest single contributor to that gap was infection: 62 infection deaths on semaglutide against 87 on placebo.[3] Under the trial’s prespecified testing order, the Wegovy label does not count the all-cause result as statistically significant; are GLP-1s longevity drugs? quotes that footnote.
Two details limit how far that number travels. First, death from any cause was never SELECT’s primary question, so it supports the main result rather than standing as a proven effect of its own; our SELECT deep dive walks through the trial’s testing order. Second, much of the trial ran during the COVID-19 pandemic. Semaglutide did not prevent COVID-19 infection. COVID-19 deaths were 43 on the drug and 65 on placebo.[3] To the extent the survival difference rests on infection deaths during the pandemic, it may not carry over to other years.
FLOW: kidneys, and death in a high-risk group
FLOW gave semaglutide 1.0 mg weekly, the diabetes dose, or placebo to 3,533 participants who had both kidney disease and type 2 diabetes. A planned interim look led to a recommendation to stop early, by which point median follow-up was 3.4 years.[4]
- Major kidney events (kidney failure, a 50% fall in kidney function, or kidney or cardiovascular death): hazard ratio 0.76 (0.66 to 0.88).[4]
- Cardiovascular death: 0.71 (0.56 to 0.89).[4]
- Death from any cause: 0.80 (0.67 to 0.95), one of the prespecified confirmatory secondary outcomes, tested in a fixed order.[4]
Of the two mortality results, FLOW’s is the cleaner: all-cause death sat inside the trial’s formal testing sequence. It also applies to a narrow group. These participants already had diabetic kidney disease, a condition with high death rates. What FLOW shows is that semaglutide slowed a disease that kills people. Our page on GLP-1 drugs and your kidneys covers the kidney side in full, and the FLOW deep dive covers the trial.
ESSENCE: the liver, briefly
ESSENCE randomized 1,197 people with biopsy-proven steatohepatitis (MASH) and moderate or advanced fibrosis to semaglutide 2.4 mg or placebo, planned for 240 weeks. At the 72-week interim in the first 800, steatohepatitis resolved without worsening fibrosis in 62.9% on semaglutide and 34.3% on placebo, and fibrosis improved in 36.8% against 22.4%. Weight fell 10.5% against 2.0%.[5]
That is a biopsy result, not a survival result. Fibrosis predicts liver failure and death, so it is a reasonable surrogate, but the 72-week report did not measure either. The fatty liver page has the detail, including why the placebo rate matters.
Why fewer deaths is not the same as slower aging
Everyone in SELECT had cardiovascular disease and excess weight. Everyone in FLOW had diabetes and damaged kidneys. A drug that lowers the death rate in those groups (and, in SELECT, the days spent in hospital) is treating diseases that shorten life. That is valuable, and it is a different claim from slowing the biology of aging in a healthy person.
Our inference, not a trial result: the most direct reading of both trials is that semaglutide reduced deaths from the conditions the participants had, plus, in SELECT, some infection deaths. Neither trial enrolled lean or metabolically healthy adults, so neither can say whether the drug would change survival in them. “Longevity drug” implies the second claim. The data support only the first.
The epigenetic clock trial
The study behind the “slows aging” headline reused blood samples from a 32-week, placebo-controlled phase 2b trial of semaglutide in adults with HIV-associated lipohypertrophy, 45 on the drug and 39 on placebo. The parent trial was designed to measure visceral fat. Researchers profiled whole-blood DNA methylation at baseline and week 32 and ran it through first-, second- and third-generation epigenetic clocks, algorithms that estimate biological age from chemical marks on DNA. The aging analysis was not prespecified. In adjusted analyses, semaglutide reduced aging across several clocks.[1]
| Clock | Change | p |
|---|---|---|
| PhenoAge | −4.9 years/year | 0.004 |
| PCGrimAge | −3.1 | 0.007 |
| GrimAge V2 | −2.3 | 0.009 |
| OMICmAge | −2.2 | 0.009 |
| RetroAge | −2.2 | 0.030 |
| DunedinPACE | −0.09 units (9% slower) | 0.01 |
Systems-based clocks showed parallel reductions in inflammation, brain and heart aging measures.[1]
The units are the trap
“Minus 4.9 years per year” is a change in rate. It is not 4.9 years removed from anybody.
That distinction disappears in almost every popular retelling of studies like this. What the number describes is how fast an estimate of biological age was moving, not a quantity of age subtracted. DunedinPACE makes it clearest: 9% slower, expressed as a pace rather than a total.
What an epigenetic clock is, and is not
These clocks are statistical models trained to predict outcomes such as mortality, disease onset and functional decline from methylation patterns. They are impressive and they are estimates. A clock reading is not a measurement of aging in the way a blood pressure is a measurement of pressure.
Which makes this a surrogate endpoint, and surrogates have a long record of moving while outcomes stay put. The same problem runs through inflammatory markers in tirzepatide and inflammation: hsCRP falls reliably, and whether anything happens to a person as a result is a separate question nobody has answered.
The limits, in the authors' own list
- Post hoc design. The aging question was asked of data collected for another purpose.
- Modest sample size. 84 participants across both arms.
- An HIV-specific cohort with lipohypertrophy, a population with distinctive metabolic and inflammatory biology.
- 32 weeks. For an aging question, that is a very short window.
The authors’ own conclusion is that prospective trials are needed to determine whether GLP-1 receptor agonists can be repurposed as gerotherapeutics.[1] That is the correct position, and it is several steps short of what the headline implies.
The other biological-age studies
A PubMed search for GLP-1 drugs and epigenetic clocks, biological age, PhenoAge, GrimAge or DunedinPACE turns up very little beyond that trial. Three items are worth knowing, and none settles the question.
- SLIM LIVER (same research group). A post hoc look at a 24-week single-arm study: 41 people with HIV and fatty liver, all on semaglutide 1.0 mg, no placebo group. Median DunedinPACE barely moved (+0.018) and median PCGrimAge rose by 0.54 years. Liver fat dropped further in the 41.5% with a falling DunedinPACE.[6] This second dataset did not reproduce a group-wide slowing, and without a control arm it could not test one.
- A drug-target Mendelian randomization study. This design uses gene variants near the GLP-1 and GIP receptors as a stand-in for lifelong drug exposure. Lower blood sugar through the GLP-1 receptor pathway was linked to greater odds of longevity, but lower BMI through that pathway was not linked to any of the four aging measures. The GIP pathway showed broader associations.[7] Genetic proxies are not the drug, and the authors ask for clinical studies.
- A prospective trial now recruiting. NCT07293325 randomizes 66 adults with obesity to semaglutide, tirzepatide or metformin for 24 weeks, open label, with change in DNA-methylation age as the primary outcome. Primary completion is estimated for April 2027.[11] It will be the first trial built to ask the clock question, and it is still short and small.
The trade-off: lean mass and frailty
Any longevity argument has to account for muscle, because muscle strength predicts independence and survival in older adults. A 2026 meta-analysis of 20 randomized trials with 15,782 participants put lean mass at 35.2% of the weight lost on semaglutide (95% CI 31.5% to 38.9%), against 25.4% on tirzepatide and 26.8% on liraglutide. Lifestyle programs produced a comparable share, 26.2%, and lifestyle plus resistance training the smallest, 17.5%.[8] Losing lean tissue is a feature of weight loss in general. Semaglutide’s share sits at the upper end. The drug versus dieting comparison goes through the numbers.
Frailty points both ways. A post hoc analysis of SELECT built a 31-item frailty index for every participant. The cardiovascular benefit looked consistent across frailty levels (interaction p = 0.09), the reduction in death from any cause did not differ by frailty, and by week 104 a shift into a less frail category was more common on semaglutide (odds ratio 2.46).[9] In the frailest group, the primary-outcome hazard ratio was 0.92 with an interval of 0.76 to 1.10. The mean age in SELECT was 61.6, so this is not a trial of the very old.
The opposite signal comes from older adults with diabetes. A 2026 review notes that short and medium-term trials in adults with obesity found handgrip strength preserved despite lean tissue loss, while longitudinal and retrospective research in older adults with type 2 diabetes has reported weaker grip and accelerated sarcopenia with prolonged semaglutide use.[10] That evidence is observational. It is also the population a longevity prescription would target. Our page on GLP-1 drugs after 65 covers it.
What has not been measured
- Lifespan. No trial has used it as an endpoint, and none could within a normal trial length.
- Death in healthy or lean adults. SELECT and FLOW enrolled people with heart disease or diabetic kidney disease. Nobody without those conditions has been randomized and followed for mortality.
- Biological age as a prespecified endpoint. Every published clock result is post hoc, and every one is in people with HIV. The first trial designed for the question is still recruiting.[11]
- Clock changes linked to outcomes. Nobody has shown that the people whose clocks slowed on semaglutide went on to live longer or stay healthier.
- Long-term muscle function in older adults. Strength, falls and disability over years of use, measured in a randomized trial, are not available.
- What happens after stopping. Whether any benefit persists once the drug is withdrawn has not been tested in an aging framework.
Where semaglutide sits among the longevity contenders
The class-wide picture, including the other GLP-1 outcome trials, is on GLP-1s as longevity drugs. Tirzepatide has its own record, with no clock data yet, on tirzepatide and longevity. The older contender is compared head to head on metformin versus GLP-1s for longevity, and the supplement end of the market is on NAD and longevity.
The last big “beyond weight” hypothesis in this class fared badly: two large randomized trials of semaglutide in early Alzheimer’s disease found no benefit.
Frequently Asked Questions
References
- 1.Corley MJ, Dwaraka VB, Pang AP, et al. Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy Nature Communications. 2026. PMID: 42156721.
- 2.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes N Engl J Med. 2023. PMID: 37952131.
- 3.Scirica BM, Lincoff AM, Lingvay I, et al. The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial J Am Coll Cardiol. 2024. PMID: 39217559.
- 4.Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes N Engl J Med. 2024. PMID: 38785209.
- 5.Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis N Engl J Med. 2025. PMID: 40305708.
- 6.Corley MJ, Pang APS, Kitch DW, et al. Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study NPJ Aging. 2026. PMID: 42014432.
- 7.Li J, Li J, Xu X, et al. Genetically proxied glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor pathway modulation is associated with favorable aging phenotypes: a drug-target Mendelian randomization study Cardiovascular Diabetology. 2026. PMID: 42642762.
- 8.Eisa N, Barood O Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials Diabetes, Obesity and Metabolism. 2026. PMID: 41877354.
- 9.Ostrominski JW, Plutzky J, Scirica BM, et al. Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial JAMA Cardiology. 2026. PMID: 42747817.
- 10.Prokopidis K Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions British Journal of Pharmacology. 2026. PMID: 41577337.
- 11.ClinicalTrials.gov Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity (NCT07293325) U.S. National Library of Medicine. 2025. https://clinicaltrials.gov/study/NCT07293325
Compare the sellers
Related research
Metformin vs GLP-1 for Longevity: The TAME Trial Has Not Started
No trial shows metformin extends life in people without diabetes. TAME, the metformin aging trial, has no registry record and was still unfunded at last report. Semaglutide has randomized outcome data, but only in people already at high risk.
9 min read
Are GLP-1s Longevity Drugs? What the Death and Outcome Data Show
GLP-1 drugs lower deaths from any cause by about 12% in people with heart disease, diabetes or kidney disease. No trial has tested them in healthy adults or measured lifespan. SELECT, FLOW, LEADER, dementia, cancer and muscle, in one place.
11 min read
Tirzepatide and Longevity: What the Death and Aging Data Show
No study shows tirzepatide extends life. In SURPASS-CVOT, 8.5% died on Mounjaro vs 10.1% on dulaglutide over four years, an exploratory result. Deaths in obesity without diabetes are unreported until 2027, and no aging-clock data exist.
11 min read
What Is NAD+? What It Does in the Body and What Supplements Claim
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme cells use to make energy and that DNA-repair enzymes consume. The body builds it from vitamin B3 and tryptophan. Pills raise it in blood, but a 2026 review covering 33 human studies calls anti-aging benefit inconclusive.
7 min read
NAD+ vs NMN: Drips and Injections vs the Oral Precursor
Oral NMN reliably raises blood NAD+ in trials, with mostly null effects on health measures. No outcome trial has tested IV or injected NAD+ for aging or wellness, and drips often cause stomach symptoms. NAD+ is in FDA's 503A Category 1; NMN is a supplement.
8 min read
NAD+ and Longevity: What the NMN and NR Trials Actually Show
NMN and nicotinamide riboside reliably raise blood NAD+, but human trials on muscle, blood sugar, blood pressure and cognition are mostly null, and none measured lifespan. Trial-by-trial effect sizes, IV NAD+, and FDA's 2025 reversal on NMN.
12 min read
Where to get semaglutide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
HumeCare+
An oral route if you will not self-inject
From $199/mo
Get started →Collective
From $59/mo + membership
Get started →Embody
From $79/mo
Get started →